CapsoVision has won FDA 510(k) clearance for AI Highlights, a software feature that flags suspected abnormal lesions inside small-bowel capsule endoscopy studies read on its CapsoCam Plus platform. FDA’s clearance letter is dated 25 September 2026; the Saratoga, California company announced it 28 September 2026, extending a device that has been used in more than 176,000 patients since 2016 — and relying, for the first time in its own regulatory history, on a competitor’s device as the clearance’s predicate.
What AI Highlights actually flags
AI Highlights works inside CapsoVision’s existing CapsoView review software and CapsoCloud workflow platform — no separate third-party software is required. For a small-bowel capsule endoscopy study performed on a patient with suspected small-bowel bleeding, it recognizes and marks frames likely to contain an abnormal lesion, prioritizing them for physician review. FDA’s clearance covers adult and pediatric patients over the age of two whose study was performed for that specific indication; the feature is not validated or labeled for other uses, such as Crohn’s disease surveillance.
CapsoVision has been explicit that AI Highlights is decision support, not a diagnosis: it is not intended to replace a gastroenterologist’s interpretation or histopathological sampling. The company has not published quantitative performance data — no sensitivity, specificity or reading-time figures — for the feature itself; the 510(k) was supported by a retrospective clinical reader study whose detailed results Regulatory News could not locate in any public source.
Three things that make this clearance unusual
Decision support, not diagnosis
AI Highlights flags suspected abnormal frames inside CapsoView for a physician to review; CapsoVision says it is not intended to replace a gastroenterologist’s interpretation or histopathological sampling.
Built on a rival’s predicate
CapsoVision’s 510(k) relies on AnX Robotica’s NaviCam ProScan — the first AI reading tool FDA authorized for this exact indication, via De Novo in April 2023 — as its predicate device.
176,000 patients before the software
CapsoCam Plus has been used in more than 176,000 patients since its original 2016 clearance; AI Highlights arrives a decade into that installed base rather than alongside a new device.
AI Highlights in four numbers
Figures from CapsoVision’s own SEC filings and press releases; the “2nd” count reflects tools Regulatory News could confirm for this specific FDA indication, not the broader AI-in-endoscopy field.
A predicate CapsoVision didn’t build
CapsoVision confirmed with FDA that it would use AnX Robotica’s NaviCam ProScan as the predicate device for AI Highlights’ traditional 510(k) submission. ProScan itself reached the market by a different, harder route: FDA granted it a De Novo request in April 2023 (DEN230027), a decision that created an entirely new device classification — “gastrointestinal capsule endoscopy analysis software”, Class II with special controls — because no predicate existed for an AI reading tool of this kind at the time. CapsoVision submitted its own 510(k) on 29 December 2025, supported by a retrospective clinical reader study, and FDA’s clearance letter is dated 25 September 2026.
The arrangement is a reminder of how narrow AI device regulation still is in this category: the company that takes the harder De Novo path effectively sets the classification and special controls every later 510(k) entrant, including a competitor, must follow. CapsoVision’s own K-number for AI Highlights had not appeared in FDA’s public 510(k) database as of this writing.
“FDA clearance of AI Highlights represents an important milestone in the continued evolution of the CapsoVision platform and our commitment to bringing integrated, AI-assisted technologies to physicians in the United States.” Kang-Huai (Johnny) Wang, President and CEO, CapsoVision — 28 September 2026 announcement
The device three companies now compete to read
Capsule endoscopy itself is a mature, modestly sized device category: Fortune Business Insights puts the global market at $523.65 million in 2026, growing to $969.2 million by 2034. The much larger figures circulating for “AI in endoscopy” — Precedence Research puts that broader software category at $21.65 billion by 2035 — describe endoscopy AI generally, not the narrow capsule-reading niche AI Highlights competes in, and should not be read as CapsoVision’s addressable market. The competitive field for capsule hardware itself is small and long-settled: Medtronic, via its Given Imaging acquisition, sells PillCam SB3 and cleared an at-home ingestion procedure for it in 2021; Olympus’s EndoCapsule has been FDA-cleared since 2007; and AnX Robotica’s NaviCam, paired with ProScan, is the only other U.S.-cleared AI reading layer Regulatory News could confirm for this indication.
AI Highlights against a small field of AI readers
| Product | U.S. regulatory status |
|---|---|
| AI Highlights (CapsoVision) | FDA 510(k) cleared, 25 September 2026, via traditional 510(k) |
| NaviCam ProScan (AnX Robotica) | FDA De Novo authorization, April 2023 (DEN230027) — the predicate CapsoVision’s clearance relies on |
| PillCam SB3 (Medtronic / Given Imaging) | Base device long-cleared; @HOME at-home ingestion 510(k) cleared Nov 2021; no dedicated AI reading-tool clearance found |
| EndoCapsule (Olympus) | Base device FDA-cleared since 2007; no dedicated AI reading-tool clearance found |
From each company’s own FDA clearance and authorization records; not a clinical comparison.
Capsule endoscopy, sized by one publisher
$523.7M → $969.2M
Global capsule endoscopy market, 2026 to 2034 forecast, per Fortune Business Insights.
Sources: Fortune Business Insights, Capsule Endoscopy Market
Regulatory News outlook
AI Highlights is a feature, not a new device, so we don’t expect it to expand the capsule endoscopy market on its own; we read it instead as a defensive move that protects CapsoVision’s existing 176,000-patient base against a rival that already offers AI-assisted reading.
How we got here: CapsoVision’s Q2 2026 revenue of $3.6 million against Fortune Business Insights’ $523.7 million 2026 capsule-endoscopy market figure implies roughly 0.7% global revenue share for the quarter; a feature clearance that keeps existing customers rather than adds new procedure volume would not be expected to move that share meaningfully.
From a 2016 clearance to an AI reading tool
CapsoCam Plus's decade before AI Highlights
- 2005
CapsoVision founded
Founded by Kang-Huai (Johnny) Wang in Saratoga, California.
- 21 October 2016
CapsoCam Plus first cleared
Original FDA 510(k) clearance (K161773) for the wire-free, panoramic capsule endoscopy system.
- 27 October 2017
EU CE Mark, ages 2 and above
CapsoCam Plus authorized for pediatric use in the European Union.
- 9 January 2025
U.S. pediatric clearance
FDA clears CapsoCam Plus for pediatric use, age 2 and above, in the United States.
- 1–2 July 2025
Nasdaq IPO
Priced at $5.00 per share; began trading as CV on 2 July 2025, raising roughly $27.5 million gross.
- 29 December 2025
AI Highlights 510(k) submitted
CapsoVision files its 510(k) for the AI-assisted reading feature, citing AnX Robotica’s ProScan as predicate.
- 3 August 2026
International launch announced
CapsoVision announces an international, EU commercial launch of AI Highlights.
- 25 September 2026
FDA clears AI Highlights
Clearance letter dated 25 September 2026; publicly announced 28 September 2026.
- Ahead
K-number expected
FDA’s public 510(k) database typically indexes a clearance within days to weeks; Regulatory News will update this page when it appears.
What the K-number still has to confirm
CapsoVision is a small company: 99 full-time employees at the end of 2025, $3.6 million in second-quarter 2026 revenue, and $9.1 million in cash as of 30 June 2026, a little over a year after its Nasdaq debut. A feature clearance like this one costs relatively little to win compared with a new device, but it still has to prove itself against real physician reading time — a number CapsoVision has not yet published.
- K-number: not yet indexed in FDA’s public 510(k) database as of this writing; Regulatory News will update this page once it is.
- Performance data: CapsoVision has not published sensitivity, specificity or reading-time figures for AI Highlights; the clearance rests on an unpublished retrospective reader study.
- EU status: an international, EU commercial launch was announced 3 August 2026; the company has not published the exact date its EU MDR technical file was authorized.
- Financials: $3.6 million in Q2 2026 revenue and $9.1 million in cash as of 30 June 2026, alongside 51% gross margin, down from 55% a year earlier.
What AI Highlights changes for a reading physician — how much time it saves, how often it agrees with a human reader — is not yet public. Regulatory News will follow up when CapsoVision or an independent study publishes that data.
Sources & further reading
- CapsoVision, “CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus,” press release, 28 September 2026. globenewswire.com
- U.S. Securities and Exchange Commission, CapsoVision Form 8-K, exhibit 99.1, 28 September 2026. sec.gov
- U.S. Food and Drug Administration, De Novo classification request summary, DEN230027 (AnX Robotica NaviCam ProScan), April 2023. accessdata.fda.gov
- CapsoVision, second-quarter 2026 financial results, press release, 13 August 2026. globenewswire.com
- CapsoVision, IPO closing announcement, investor relations, 3 July 2025. investors.capsovision.com
- CapsoVision, “CapsoVision Announces International Launch of AI Highlights,” press release, 3 August 2026. globenewswire.com
- U.S. Food and Drug Administration, 510(k) summary K161773 (CapsoCam Plus), 21 October 2016. accessdata.fda.gov
- Fortune Business Insights, Capsule Endoscopy Market. fortunebusinessinsights.com
- Precedence Research, AI in Endoscopy Market. precedenceresearch.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA clear for CapsoVision?
AI Highlights, a software feature inside CapsoVision's existing CapsoView and CapsoCloud platforms that flags images likely to contain abnormal lesions in small-bowel capsule endoscopy studies performed for suspected small-bowel bleeding. FDA's clearance letter is dated 25 September 2026; CapsoVision announced it 28 September 2026.
Does AI Highlights replace a physician's reading?
No. It is decision support: it flags and prioritizes suspected abnormal frames for a trained physician to review. It is not intended to replace a gastroenterologist's diagnostic interpretation or histopathological sampling.
What device did FDA use as the predicate for this clearance?
AnX Robotica's NaviCam ProScan, an AI-assisted reading tool a competitor won FDA De Novo authorization for in April 2023 (DEN230027) — the decision that created the device classification CapsoVision's 510(k) relies on.
Is CapsoVision publicly traded?
Yes, on the Nasdaq Capital Market under the ticker CV, since its IPO priced 1 July 2025. It reported $3.6 million in second-quarter 2026 revenue and $9.1 million in cash as of 30 June 2026.
